Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.54 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11877575 | 0.87 | HTT (0.59) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL11372755 | 0.85 | HTT (0.50) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL11853007 | 0.84 | HTT (0.49) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL11537672 | 0.84 | PDK1 (0.50) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL12584932 | 0.84 | HTT (0.69) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL750651 | 0.83 | RIPK1 (0.59) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL8321463 | 0.83 | PDK1 (0.61) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL3295838 | 0.83 | PDK1 (0.61) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL8178597 | 0.82 | HTT (0.67) | HTTLMNAMEN1KMT2AMAPT | |
| SCHEMBL11283348 | 0.81 | MAPT (0.51) | HTTLMNAMAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273012-B2 | Facile preparation of 4-substituted quinazolines and related heterocycles | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-03-01 | — | — | US | disclosed |
| US-20120283436-A1 | FACILE PREPARATION OF 4-SUBSTITUTED QUINAZOLINES AND RELATED HETEROCYCLES | THE UNIVERSITY OF HOUSTON (US) | 2012-11-08 | — | — | US | disclosed |
| EP-1330456-B8 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| US-7115619-B2 | N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330456-A2 | N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | TERT, MKI67, NQO2 | HTT 1530/4885LMNA 450/4885MEN1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.